EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyse

The Effect of Thiazolidinediones in Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis of Randomised Controlled Trials

Mohammed A Abdalla iD, Najeeb Shah, Harshal Deshmukh, Amirhossein Sahebkar, Linda Östlundh, Rami H Al-Rifai, Stephen L Atkin, Thozhukat Sathyapalan

Advances in Therapy · 2024

DOI: 10.1007/s12325-024-02848-3 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Advances in Therapy, 2024. Verfasst von Mohammed A Abdalla und 7 weiteren Autor:innen. Beteiligte Einrichtung: Allam Diabetes Centre, Academic Diabetes, Endocrinology and Metabolism, The University of Hull, Hull York Medical School (HYMS), Hull, UK. mohammed.a…. Hauptthemen laut MEDLINE: Polycystic Ovary Syndrome, Randomized Controlled Trials as Topic, Hypoglycemic Agents, Pioglitazone. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 56 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Polycystic ovary syndrome (PCOS) is a complex endocrine condition affecting women of reproductive age. It is characterised by insulin resistance and is a risk for type 2 diabetes mellitus (T2DM). The aim of this study was to review the literature on the effect of pioglitazone and rosiglitazone in women with PCOS. METHODS: We searched PubMed, MEDLINE, Scopus, Embase, Cochrane Library and the Web of Science in April 2020 and updated in March 2023. Studies were deemed eligible if they were randomised controlled trials (RCTs) reporting the effect of pioglitazone and rosiglitazone in PCOS. The study follows the 2020 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). Two reviewers independently extracted data and assessed the risk of bias using the Cochrane risk of bias tool. RESULTS: Out of 814 initially retrieved citations, 24 randomised clinical trials (RCTs) involving 976 participants were deemed eligible. Among women with PCOS, treatment with rosiglitazone compared to metformin resulted in a significant increase in the mean body weight (mean difference (MD) 1.95 kg; 95% CI 0.03-3.87, p = 0.05). Metformin treatment was associated with a reduction in mean body mass index (BMI) compared to pioglitazone (MD 0.85 kg/m2; 95% CI 0.13-1.57, p = 0.02). Both pioglitazone compared to placebo (MD 2.56 kg/m2; 95% CI 1.77-3.34, p < 0.00001) and rosiglitazone compared to metformin (MD 0.74 kg/m2; 95% CI 0.07-1.41, p = 0.03) were associated with a significant increase in BMI. Treatment with pioglitazone compared to placebo showed a significant reduction in triglycerides (MD - 0.20 mmol/L; 95% CI - 0.38 to - 0.03, p = 0.02) and fasting insulin levels (MD - 11.47 mmol/L; 95% CI - 20.20, - 2.27, p = 0.01). Rosiglitazone compared to metformin was marginally significantly associated with a reduction in the luteinising hormone (LH) (MD - 0.62; 95% CI - 1.25-0.00, p = 0.05). CONCLUSION: Both pioglitazone and rosiglitazone were associated with significant increases in body weight and BMI when compared with metformin or placebo. Pioglitazone significantly reduced triglycerides and fasting insulin when compared with placebo while rosiglitazone showed a modest reduction of LH when compared with metformin. PROSPERO REGISTRATION NO: CRD42020178783.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Polycystic Ovary SyndromeRandomized Controlled Trials as TopicHypoglycemic AgentsPioglitazoneRosiglitazoneHumansFemaleThiazolidinedionesMetforminDiabetes Mellitus, Type 2Body Mass Index

Stichwörter der Autor:innen

FBGFIGlitazonesHOMA-BHOMA-IRMetforminPCOSPharmacological therapyPioglitazonePolycystic ovary syndromeRosiglitazone

Substanzen

Hypoglycemic AgentsPioglitazoneRosiglitazoneThiazolidinedionesMetformin

Autor:innen und Institutionen

  • Allam Diabetes Centre, Academic Diabetes, Endocrinology and Metabolism, The University of Hull, Hull York Medical School (HYMS), Hull, UK. mohammed.ahmed@dasmaninstitute.org.
  • Dasman Diabetes Institute, Department of Translational Research, State of Kuwait, Kuwait City, Kuwait. mohammed.ahmed@dasmaninstitute.org.
  • Allam Diabetes Centre, Academic Diabetes, Endocrinology and Metabolism, The University of Hull, Hull York Medical School (HYMS), Hull, UK.
  • Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Applied Biomedical Research Centre, Mashhad University of Medical Sciences, Mashhad, Iran.
  • School of Medicine, The University of Western Australia, Perth, Australia.

ORCID-Profile: Mohammed A Abdalla

Zitieren

APA

Abdalla, M. A., Shah, N., Deshmukh, H., Sahebkar, A., Östlundh, L., Al-Rifai, R. H., Atkin, S. L., & Sathyapalan, T. (2024). The Effect of Thiazolidinediones in Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. Advances in Therapy. https://doi.org/10.1007/s12325-024-02848-3

Vancouver

Abdalla MA, Shah N, Deshmukh H, Sahebkar A, Östlundh L, Al-Rifai RH, et al. The Effect of Thiazolidinediones in Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. Advances in Therapy. 2024. doi:10.1007/s12325-024-02848-3

BibTeX
@article{Abdalla2024,
  author = {Abdalla, Mohammed A and Shah, Najeeb and Deshmukh, Harshal and Sahebkar, Amirhossein and Östlundh, Linda and Al-Rifai, Rami H and Atkin, Stephen L and Sathyapalan, Thozhukat},
  title = {The Effect of Thiazolidinediones in Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis of Randomised Controlled Trials},
  journal = {Advances in Therapy},
  year = {2024},
  doi = {10.1007/s12325-024-02848-3}
}
Kostenlos starten →